BriaCell is a clinical stage #immunotherapy company developing treatments that boost the ability of the body’s own cancer-fighting cells to destroy cancerous tumors. Learn more: https://t.co/qcbWKEaR2J $BCTX $BCTXW
Awarded Fast Track status by the U.S. Food and Drug Administration (FDA), BriaCell’s lead candidate, Bria-IMT™, is being evaluated in a Phase II clinical trial in advanced #breastcancer. Learn about Bria-IMT™: https://t.co/k7BOaR8BCI $BCTX $BCTXW
2) Successful completion of the pivotal study could be followed by a Biologics License Application submission & commercialization; 3) Pivotal study's primary endpoint to be linked to survival improvement. Read the letter to shareholders here: https://t.co/pnLA1H5d6W $BCTX $BCTXW
Highlights from the letter include: 1) Positive FDA feedback on our pivotal study for lead clinical candidate Bria-IMT™ in combination with a checkpoint inhibitor could greatly accelerate the path to commercialization. https://t.co/pnLA1H5d6W $BCTX $BCTXW
BriaCell today issues a letter to shareholders from Dr. William V. Williams, BriaCell's President and CEO. Read more: https://t.co/pnLA1H5d6W $BCTX $BCTXW
BriaCell recently announced positive clinical and quality of life data in advanced metastatic #breastcancer at the 2022 @SABCSSanAntonio. Find the details here: https://t.co/V0UGrE1aoe $BCTX $BCTXW #SABCS22
Positive efficacy data from BriaCell's Phase I/IIa clinical study of Bria-IMT™ in combination with Incyte’s retifanlimab for the treatment of advanced #breastcancer was summarized in our poster session at the @sitcancer 37th Annual Meeting. https://t.co/j8qvbfmjJM $BCTX $BCTXW
BriaCell is pleased to announce positive initial efficacy data in its 2021-2022 cohort of 12 advanced #breastcancer patients. For details: https://t.co/WrLr4VQZL8 $BCTX $BCTXW
Disease control, tumor shrinkage, and potential survival benefit were observed amongst 12 patients in the Phase I/IIa clinical study of Bria-IMT™ in combination with Incyte’s retifanlimab. https://t.co/WrLr4W82N8 $BCTX $BCTXW
We are looking forward to our poster presentation, "An off-the-shelf personalized cellular approach to #immunothrapy for the treatment of advanced solid tumors" at the 2022 Society for Immunotherapy of Cancer Annual Meeting on November 10th. https://t.co/LEyoYS3tV5 $BCTX $BCTXW